Development of Vitrification Process and Glass Formulation for Nuclear Waste Conditioning

The vitrification of high-level waste is the internationally recognized standard to minimize the impact to the environment resulting from waste disposal as well as to minimize the volume of conditioned waste to be disposed of. COGEMA has been vitrifying high-level waste industrially for over 20 years and is currently operating three commercial vitrification facilities based on a hot metal crucible technology, with outstanding records of safety, reliability and product quality. To further increase the performance of vitrification facilities, CEA and COGEMA have been developing the cold crucible melter technology since the beginning of the 1980s. This type of melter is characterized by a virtually unlimited equipment service life and a great flexibility in dealing with various types of waste and allowing development of high temperature matrices. In complement of and in parallel with the vitrification process, a glass formulation methodology has been developed by the CEA in order to tailor matrices for the wastes to be conditioned while providing the best adaptation to the processing technology. The development of a glass formulation is a trade-off between material properties and qualities, technical feasibility, and disposal safety criteria. It involves non-radioactive and radioactive laboratories in order to achieve a comprehensive matrix qualification. Several glasses and glass ceramics have thus been studied by the CEA to be compliant with industrial needs and waste characteristics: glasses or other matrices for a large spectrum of fission products, or for high contents of specifics elements such as sodium, phosphate, iron, molybdenum, or actinides. New glasses or glass-ceramics designed to minimize the final wasteform volume for solutions produced during the reprocessing of high burnup fuels or to treat legacy wastes are now under development and take benefit from the latest CEA hot-laboratories and technology development. The paper presents the CEA state-of-the-art in developing matrices or glasses and provides several examples

DNA-PK Is Targeted by Multiple Vaccinia Virus Proteins to Inhibit DNA Sensing

Virus infection is sensed by pattern recognition receptors (PRRs) detecting virus nucleic acids and initiating an innate immune response. DNA-dependent protein kinase (DNA-PK) is a PRR that binds cytosolic DNA and is antagonized by vaccinia virus (VACV) protein C16. Here, VACV protein C4 is also shown to antagonize DNA-PK by binding to Ku and blocking Ku binding to DNA, leading to a reduced production of cytokines and chemokines in vivo and a diminished recruitment of inflammatory cells. C4 and C16 share redundancy in that a double deletion virus has reduced virulence not seen with single deletion viruses following intradermal infection. However, non-redundant functions exist because both single deletion viruses display attenuated virulence compared to wild-type VACV after intranasal infection. It is notable that VACV expresses two proteins to antagonize DNA-PK, but it is not known to target other DNA sensors, emphasizing the importance of this PRR in the response to infection in vivo

More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients

BackgroundThe clinical outcome of COVID-19 pneumonia is highly variable. Few biological predictive factors have been identified. Genetic and immunological studies suggest that type 1 interferons (IFN) are essential to control SARS-CoV-2 infection.ObjectiveTo study the link between change in blood IFN-α2 level and plasma SARS-Cov2 viral load over time and subsequent death in patients with severe and critical COVID-19.MethodsOne hundred and forty patients from the CORIMUNO-19 cohort hospitalized with severe or critical COVID-19 pneumonia, all requiring oxygen or ventilation, were prospectively studied. Blood IFN-α2 was evaluated using the Single Molecule Array technology. Anti-IFN-α2 auto-Abs were determined with a reporter luciferase activity. Plasma SARS-Cov2 viral load was measured using droplet digital PCR targeting the Nucleocapsid gene of the SARS-CoV-2 positive-strand RNA genome.ResultsAlthough the percentage of plasmacytoid dendritic cells was low, the blood IFN-α2 level was higher in patients than in healthy controls and was correlated to SARS-CoV-2 plasma viral load at entry. Neutralizing anti-IFN-α2 auto-antibodies were detected in 5% of patients, associated with a lower baseline level of blood IFN-α2. A longitudinal analysis found that a more rapid decline of blood IFN-α2 was observed in fatal versus surviving patients: mortality HR=3.15 (95% CI 1.14–8.66) in rapid versus slow decliners. Likewise, a high level of plasma SARS-CoV-2 RNA was associated with death risk in patients with severe COVID-19.ConclusionThese findings could suggest an interest in evaluating type 1 IFN treatment in patients with severe COVID-19 and type 1 IFN decline, eventually combined with anti-inflammatory drugs.Clinical trial registrationhttps://clinicaltrials.gov, identifiers NCT04324073, NCT04331808, NCT04341584

Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariants BA.2.75.2 and BQ.1.1 are expected to become predominant in many countries in November 2022. They carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and Imdevimab) and Evusheld (Cilgavimab and Tixagevimab) lost any antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas Xevudy (Sotrovimab) remained weakly active. BQ.1.1 was also resistant to Bebtelovimab. Neutralizing titers in triply vaccinated individuals were low to undetectable against BQ.1.1 and BA.2.75.2, 4 months after boosting. A BA.1/BA.2 breakthrough infection increased these titers, which remained about 18-fold lower against BA.2.75.2 and BQ.1.1, than against BA.1. Reciprocally, a BA.5 breakthrough infection increased more efficiently neutralization against BA.5 and BQ.1.1 than against BA.2.75.2. Thus, the evolution trajectory of novel Omicron subvariants facilitated their spread in immunized populations and raises concerns about the efficacy of most currently available mAbs.N

Comparaison des propriétés antiapoptotiques de quatre protéines du virus de la vaccine en isolement et au cours de l’infection virale.

Apoptosis, which occurs following activation of effector caspases, can restrict the replication of intracellular pathogens, especially viruses. Vaccinia virus (VACV) is a large dsDNA virus encoding approximately 200 proteins, several of which inhibit apoptosis. This redundancy of viral anti-apoptotic proteins complicates the study of these proteins in the context of viral infection. Here a comparative study of the anti-apoptotic proteins B13, F1, GAAP and N1 with and without virus infection is presented. Firstly, using lentiviral constructs, we generated transduced cell lines expressing the anti-apoptotic proteins in isolation and we analysed their ability to protect against extrinsic and intrinsic apoptosis induced by different drugs. In that context B13 was the most potent inhibitor of intrinsic apoptosis and the only protein to inhibit both extrinsic and intrinsic apoptosis. We then used a deficient VACV strain, vv811, that lacks the genes coding for the four anti-apoptotic proteins. Infection with vv811 can induce apoptosis without the need for any other stimulus. After vv811 infection of cell lines expressing the anti-apoptotic proteins in trans, B13 and to a lesser extent F1, inhibited apoptosis. Finally, we introduced each gene separately into vv811 by genetic recombination. Using these recombinant viruses to induce apoptosis, B13 and F1 were very potent inhibitors. The protection conferred by GAAP was cell type dependant and N1 failed to protect any of the tested cells from the virus induced apoptosis. Using these different approaches, we have been able to overcome the redundancy issue to compare 4 anti-apoptotic proteins from VACV, including in the context of viral infection. The results illustrate that vv811 is a useful tool to determine the role of VACV anti-apoptotic proteins during infection and that whilst all of these proteins have some anti-apoptotic activity, B13 is most potent.L’apoptose, mort cellulaire observée suite à l’activation des caspases effectrices, est un moyen de défense contre les pathogènes, en particulier les virus. Le virus de la vaccine (VACV) est un virus contenant un grand génome à ADN codant pour environ 200 protéines, dont plusieurs inhibent l’apoptose. Cette apparente redondance fonctionnelle complique l’étude des protéines antiapoptotiques du virus dans un contexte d’infection virale. Dans ce travail, nous comparerons les propriétés antiapoptotiques des protéines B13, F1, GAAP et N1 de VACV. Cette comparaison sera établie dans un premier temps en dehors de toute infection virale. En utilisant des vecteurs lentiviraux, nous avons obtenu des lignées cellulaires stables (U2-OS) exprimant ces protéines en isolation. Nous avons alors pu tester les capacités antiapoptotiques de ces protéines en réponse à des stimuli provoquant l’apoptose extrinsèque et intrinsèque. Les résultats ont montré que B13 était la plus puissante molécule inhibitrice de l’apoptose intrinsèque et qu’elle était la seule à inhiber l’apoptose extrinsèque. Ensuite nous avons tiré avantage d’un virus de la vaccine déficient (vv811) qui ne possède aucune de ces protéines antiapoptotiques, capable à lui seul d’induire l’apoptose, en l’absence de toute autre stimulus. En infectant nos lignées cellulaires exprimant les molécules in trans avec vv811, nous avons pu montrer que B13 inhibait cette apoptose induite par le virus beaucoup plus efficacement que F1. GAAP et N1 dans ce contexte n’ont pas démontré de propriétés antiapoptotiques. Enfin, nous avons construit par mutagénèse des virus vv811 recombinants exprimant les molécules étudiées in cis. Suite à l’infection par ces virus de cellules U2-OS et Hela, B13, de nouveau, et F1 ont montré des capacités d’inhibition importantes de l’apoptose. L’action de GAAP s’est révélée dépendante du type cellulaire et N1 n’a pas pu inhiber l’apoptose induite par ce virus déficient dans aucune des cellules testées. En utilisant ces différentes approches, nous avons pu nous affranchir des problèmes de redondance et comparer 4 molécules antiapoptotiques du virus de la vaccine, y compris dans un contexte d’infection virale. Les résultats ont confirmé que toutes les protéines étudiées possédaient des propriétés antiapoptiques et ont clairement montré que B13 était la plus puissant

Comparison of the anti-apoptotic properties of 4 vaccinia virus proteins in isolation and during viral infection

L’apoptose, mort cellulaire observée suite à l’activation des caspases effectrices, est un moyen de défense contre les pathogènes, en particulier les virus. Le virus de la vaccine (VACV) est un virus contenant un grand génome à ADN codant pour environ 200 protéines, dont plusieurs inhibent l’apoptose. Cette apparente redondance fonctionnelle complique l’étude des protéines antiapoptotiques du virus dans un contexte d’infection virale. Dans ce travail, nous comparerons les propriétés antiapoptotiques des protéines B13, F1, GAAP et N1 de VACV. Cette comparaison sera établie dans un premier temps en dehors de toute infection virale. En utilisant des vecteurs lentiviraux, nous avons obtenu des lignées cellulaires stables (U2-OS) exprimant ces protéines en isolation. Nous avons alors pu tester les capacités antiapoptotiques de ces protéines en réponse à des stimuli provoquant l’apoptose extrinsèque et intrinsèque. Les résultats ont montré que B13 était la plus puissante molécule inhibitrice de l’apoptose intrinsèque et qu’elle était la seule à inhiber l’apoptose extrinsèque. Ensuite nous avons tiré avantage d’un virus de la vaccine déficient (vv811) qui ne possède aucune de ces protéines antiapoptotiques, capable à lui seul d’induire l’apoptose, en l’absence de toute autre stimulus. En infectant nos lignées cellulaires exprimant les molécules in trans avec vv811, nous avons pu montrer que B13 inhibait cette apoptose induite par le virus beaucoup plus efficacement que F1. GAAP et N1 dans ce contexte n’ont pas démontré de propriétés antiapoptotiques. Enfin, nous avons construit par mutagénèse des virus vv811 recombinants exprimant les molécules étudiées in cis. Suite à l’infection par ces virus de cellules U2-OS et Hela, B13, de nouveau, et F1 ont montré des capacités d’inhibition importantes de l’apoptose. L’action de GAAP s’est révélée dépendante du type cellulaire et N1 n’a pas pu inhiber l’apoptose induite par ce virus déficient dans aucune des cellules testées. En utilisant ces différentes approches, nous avons pu nous affranchir des problèmes de redondance et comparer 4 molécules antiapoptotiques du virus de la vaccine, y compris dans un contexte d’infection virale. Les résultats ont confirmé que toutes les protéines étudiées possédaient des propriétés antiapoptiques et ont clairement montré que B13 était la plus puissanteApoptosis, which occurs following activation of effector caspases, can restrict the replication of intracellular pathogens, especially viruses. Vaccinia virus (VACV) is a large dsDNA virus encoding approximately 200 proteins, several of which inhibit apoptosis. This redundancy of viral anti-apoptotic proteins complicates the study of these proteins in the context of viral infection. Here a comparative study of the anti-apoptotic proteins B13, F1, GAAP and N1 with and without virus infection is presented. Firstly, using lentiviral constructs, we generated transduced cell lines expressing the anti-apoptotic proteins in isolation and we analysed their ability to protect against extrinsic and intrinsic apoptosis induced by different drugs. In that context B13 was the most potent inhibitor of intrinsic apoptosis and the only protein to inhibit both extrinsic and intrinsic apoptosis. We then used a deficient VACV strain, vv811, that lacks the genes coding for the four anti-apoptotic proteins. Infection with vv811 can induce apoptosis without the need for any other stimulus. After vv811 infection of cell lines expressing the anti-apoptotic proteins in trans, B13 and to a lesser extent F1, inhibited apoptosis. Finally, we introduced each gene separately into vv811 by genetic recombination. Using these recombinant viruses to induce apoptosis, B13 and F1 were very potent inhibitors. The protection conferred by GAAP was cell type dependant and N1 failed to protect any of the tested cells from the virus induced apoptosis. Using these different approaches, we have been able to overcome the redundancy issue to compare 4 anti-apoptotic proteins from VACV, including in the context of viral infection. The results illustrate that vv811 is a useful tool to determine the role of VACV anti-apoptotic proteins during infection and that whilst all of these proteins have some anti-apoptotic activity, B13 is most potent

Nihilismo y metafísica en Danilo Cruz Vélez

El propósito de este escrito es estudiar las investigaciones de Danilo Cruz Vélez sobre el nihilismo nietzscheano en relación con la metafísica. Para la consecución de este objetivo, se requieren parámetros para la comparación entre los trabajos y escritos del pensador colombiano con los estudios e investigaciones de Martin Heidegger, con el fin de establecer los nexos e influencias del pensador alemán en nuestro eximio filósofo colombiano. Lo anterior nos permite concluir, con la autoridad y el rigor de los textos mismos, que las tesis de Cruz Vélez a este respecto no son más que la traducción del alemán al español de los estudios de Heidegger sobre Nietzsche, cosa que se produce como consecuencia de los seminarios impartidos por Heidegger en  la universidad de Friburgo, a los cuales asistió Danilo Cruz Vélez en calidad de estudiante. 

Pharmacie clinique basée sur les preuves à l’officine : évaluation et perspectives

Evidence Based Medecine (EBM) is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of the individual patient. This practice should be used in order to optimize patient care. The goal of this study was to evaluate the level of Evidence Based Practice (EBP) of the community pharmacists of France, and to investigate the factors linked to this practice. We created and broadcasted an online questionary to evaluate the level of EBP of the french pharmacists on 4 typical clinical cases, related to conventional medicine and alternative and complementary medicine. We then analysed these data using descriptive and inferential statistics (univariate and multivariate analysis). We collected 595 pharmacist answers. The EBP level of our sample is mixed, with only 11% of respondants getting the maximal score on every case. The explicative factors were the quality and quantity of information sources used by the pharmacist, as well as the type of the continuous training he get. This highlighted the importance of learning to recognize the best sources and how to use them, as soon as the university training. The students must learn to develop their critical mind to be able to face the conflicts of interest existing in the healthcare system. The profile of the owner-pharmacist is linked to a lower score, compared to the other profiles (non-owner pharmacists and 6th grade community pharmacy students). The pharmacists must be encouraged to a more evidence based practice, to be recognized as scientific and reliable healthcare providers, thus legitimate to an important role in the patient system care.L’Evidence Based Medicine est définie comme l’utilisation consciencieuse, explicite et judicieuse des meilleures preuves médicales actuelles dans toute prise de décision concernant la prise en charge personnalisée de chaque patient. Le but de cette étude était de connaître le niveau de pratique basée sur les preuves (EBP) des pharmaciens d’officine en France et les facteurs l’influençant. Nous avons construit puis diffusé un questionnaire en ligne pour tester le niveau d’EBP du pharmacien d’officine sur la base de 4 cas cliniques. Les données récoltées ont été analysées de manière descriptive puis explicative (analyses univariées et multivariées). 595 réponses ont été récoltées. Le niveau d’EBP de notre population apparaît mitigé, avec 11% de score optimal sur les cas cliniques. La qualité et la quantité des sources d’informations utilisées par le pharmacien et le type de formation continue pratiquée influencent le niveau d’EBP, d’où la nécessité d’apprendre à distinguer et à utiliser les meilleures sources dès la formation initiale. Les étudiants doivent apprendre à développer leur esprit critique, pour faire face aux conflits d’intérêts existant dans le monde de la santé. Le profil « titulaire » est associé à un score final plus faible comparé aux autres profils de pharmaciens exerçants au sein de l’officine (adjoints, remplaçants, étudiants en 6ème année d’officine). Les pharmaciens doivent être encouragés à avoir une pratique basée sur les preuves, afin d’être reconnus comme des professionnels scientifiques, responsables, et donc légitimes à une place importante dans la prise en charge des patients

Histoire et renouveau de l'absinthe

CHATENAY M.-PARIS 11-BU Pharma. (920192101) / SudocSudocFranceF